China To Invest $1 Billion To Ramp Up New Drug Innovation
SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009
More from Archive
More from Scrip
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.